INTRODUCTION
humoral and cellular immune responses, but these have been shown to decline with time in both animal studies Herpes simplex virus (HSV) is a common human (Meigner et al., 1987) and human trials (Mertz et al., 1984) pathogen that causes significant morbidity in its various and have been nonprotective in humans (Mertz et al., disease manifestations, which include encephalitis, ker-1990; Corey, 1991) . Recombinant HSV glycoproteins have atitis, and disseminated disease of the newborn (Roizalso been employed with potent adjuvants and are proman, 1991; Whitley, 1996) . In addition to acute infection tective in animal model systems against acute infection which initiates at a mucosal or epithelial surface, the and establishment of latent infection (Dix and Mills, 1985 ; virus can establish a latent infection of sensory neurons Manservigi et al., 1990a Manservigi et al., , 1990b Langenberg et al., 1995 ; innervating the infected mucosa. Once latency is estab- Mishkin et al., 1991) and reduce the number of ganglia lished in the nervous system, the virus is apparently imexpressing the latency-associated transcript (Burke et pervious to elimination by the host immune response. al., 1991) . Both adenoviruses and vaccinia viruses have Periodic reactivation from latency leads to recurrent epibeen used as vectors to express HSV glycoproteins as sodes of disease that can be debilitating, as in the case a form of live virus vaccine (Burke, 1992; Gallichan et al. , of keratitis, the second most common cause of corneal 1993). The vaccinia vectors have been shown to elicit blindness (Whitley, 1996) . Because of the multiple stages immune responses in mice that can reduce disease of HSV infection, effective vaccination will require the (Cantin et al., 1983; Paoletti et al., 1984; Cremer et al. , induced immune response to intervene in the establish-1985; Weir et al., 1989; Blacklaws et al., 1990) and latent ment of latent infection as well as reduce the severity of infection (Cremer et al., 1985; Blacklaws et al., 1990) . acute disease. Third, the immunity must be long-lasting.
In addition, durable immunity was elicited in mice by a Numerous approaches to immunization against HSV vaccinia virus vector expressing HSV gD (Rooney et al., have been tried, including inactivated virus, live attenu-1988) , as would be expected of a live-virus vaccine ated virus, glycoprotein subunits, and heterologous virus (Burke, 1992) . The utility of vaccinia vectors may be limvectors expressing HSV glycoproteins (reviewed in ited by their poor immunogenicity in vaccinia-immune Burke, 1992) . HSV glycoprotein formulations elicit both individuals (Cooney et al., 1993; Hammond et al., 1992) . Replication-impaired mutant HSV strains have also been examined for their capacity to induce protective responses, while possessing the safety of an inactivated strain is a replication-defective mutant of the KOS1.1 strain bearing a deletion in the UL29 gene encoding ICP8 vaccine. One form of replication-impaired virus lacks a viral gene product essential for progeny virus production (Gao and Knipe, 1989) . This virus expresses products of a, b, and g1 gene classes in infected normal cells but (Gao and Knipe, 1989; Rice and Knipe, 1990) . These mutants express viral proteins in infected cells but cannot cannot replicate and must be propagated on a cell line, S2, which is stably transformed with the UL29 gene. replicate in the host, and must be propagated in vitro on a cell line that complements the defective gene product.
Stocks of all viruses were prepared by inoculating Vero or S2 cell monolayers at low multiplicity of infection (0.1 We had previously observed that mice immunized twice subcutaneously with d301, a replication-defective virus PFU/cell) and incubating at 34Њ in 199 medium containing 1% FCS. Cells were collected when rounded and decontaining a deletion in the gene encoding ICP8 (Gao and Knipe, 1989) , mount an immune response similar to taching and pelleted at 300 g for 10 min at 4Њ. Cell pellets were resuspended in culture supernatant plus an equal that seen in mice immunized with the wt parental strain, KOS1.1 (Morrison and Knipe, 1994) . When challenged 1 volume of sterile nonfat milk (0.91), frozen at 080Њ, thawed, and disrupted by sonication (Heat Systems, Farmonth later by corneal inoculation of a virulent HSV-1 strain, the mice were completely protected from developmingdale, New York) three times for 30 sec each on ice.
Lysates were clarified by centrifugation at 300 g for 10 ment of keratitis and encephalitis and from latent infection of the nervous system (Morrison and Knipe, 1994) . min, and aliquots were stored frozen at 080Њ. Lysate of uninfected Vero cell monolayers was prepared as a con-A second form of mutant HSV-1 lacking gH, and therefore capable of undergoing a single round of replication in trol (control cell lysate). Partially purified KOS1.1 was prepared by harvesting the culture medium of infected infected cells, has been shown to protect against disease in a mouse skin model (Farrell et al., 1994) and a guinea Vero cell monolayers, subjecting the supernatant to low speed centrifugation to remove detached cells, and then pig genital model .
Little is known about the mechanisms by which the pelleting the virus at 27,000 g for 45 min at 4Њ. Virus pellets were resuspended in 199 medium containing 15% replication-defective mutant viruses induce protective immunity against latent infection by challenge virus or, in glycerol, sonicated for 15 sec, and stored at 080Њ. Wildtype KOS1.1 and mP strains were titered on Vero cells, general, how live viruses induce protective immunity against persistent infection. The studies in this report and d301 was titered on S2 cells. Although titered on Vero cells, KOS1.1 grows equally well on Vero and S2 address three questions regarding these mechanisms. First, does immunization with replication-defective mucells (Gao and Knipe, 1991) . Because inactivated virus particles are not effective for induction of immune retant HSV reduce establishment of latent infection by the challenge virus or merely its ability to reactivate? A responses in this system (Morrison and Knipe, 1994) , the number of viral genomes capable of entering cells is lated issue is whether the mutant virus establishes latency in the neurons and interferes with establishment a more valid comparison of different viral stocks than particle:PFU ratios. Cells exposed to equal numbers of of latent infection by the challenge virus, as hypothesized for the live attenuated SIV vaccine viruses in T lympho-PFU's of KOS1.1 wt and d301 contain approximately equal amounts of viral DNA at 1 hr postinfection (hpi) cytes (Rud et al., 1994) . Second, is the immunity induced by the replication-defective mutant virus durable? Live (Gao and Knipe, 1993) . Thus, the two viral stocks seemed to be comparable in terms of genomes capable of enterviruses are known to elicit long-lived immunity in the host while killed or subunit vaccines elicit a less durable ing host cells. immunity. Replication-defective mutant viruses share properties with each of these two forms of vaccine in Animals and inoculations that they infect cells and express endogenous viral antigens like a live virus but fail to spread within the host Female BALB/c mice, 6 weeks of age, were purchased from the National Cancer Institute (Fredericksburg, MD) similar to an inactivated or subunit vaccine. Thus, it is not apparent how durable the immune responses to replior Taconic (Germantown, NY) and were acclimated 1 week before use. The mice were housed in accordance cation-defective mutant viruses would be. Third, how can a replication-defective virus induce an immune response with institutional policies and National Institutes of Health guidelines (Committee on Care and Use of Labothat is comparable to that induced by a virus that spreads within the host?
ratory Animals, 1985) . For immunization, hair on the left rear flank of each mouse was trimmed and 2 1 10 6 PFU of d301 or wt KOS1.1 virus, or an equivalent amount of MATERIALS AND METHODS control cell lysate, were inoculated by subcutaneous Cells and viruses (s.c.) injection of a 20-ml vol using a 26-gauge needle. Secondary immunizations were given 4 weeks later in The wild-type (wt) KOS1.1 and microplaque (mP) (Hoggan and Roizman, 1959) strains of identical fashion. At 1, 4, or 7 months after the final immunization, groups HSV-1 were grown on Vero cell monolayers. The d301 of six to nine mice were anesthetized and challenged by section was collected and hybridized with a 35 S-labeled DNA probe, pIPH (Leib et al., 1989) , to detect LAT. In inoculation onto the scarified corneas of 1 1 10 5 PFU/ eye of the HSV-1 mP strain as previously described (Coen situ hybridization was performed as previously described (Haase et al., 1984; Stroop et al., 1984; Leib et al., 1989 Leib et al., ). et al., 1989 , except that the volume of the inoculum was 5 ml.
Statistical analyses Clinical observations and keratitis scoring
Fisher's exact test with P values in 1 tail were used to Mice were observed daily in the period postchallenge determine the significance of differences in the proporfor clinical signs of encephalitis: ruffled fur, hunched postion of latently infected trigeminal ganglia between mice ture, ataxia, and anorexia. Keratitis scores, representing inoculated with control cell lysate and those immunized both severity and extent of disease, were determined for with d301 or KOS1.1. The significance of differences in each eye of challenged mice as described previously the number of LAT / neurons per section was determined (Morrison and Knipe, 1994) .
by the two sample t test for independent samples. Assays of acute and latent infection Determination of neutralizing antibody titers To assess acute replication at various times after corneal challenge, the eyes of each mouse were individually Blood was collected from the tail veins of groups of swabbed with moistened cotton-tipped applicators. The five to seven mice at various times after immunization. two swabs from each mouse were placed together in Sera from each group were pooled and stored at 020Њ. vials containing 1 ml assay medium (PBS containing 0.1% When all serum samples had been collected, compleglucose and 1% FCS) and stored frozen at 080Њ until ment-dependent and -independent neutralizing antibody time of assay. Viral titers were determined by standard titers were determined by a CPE inhibition assay. Sera plaque assay on Vero cells .
were serially diluted in twofold steps beginning at 1:4 in To assess replication in vivo of mutant and wt virus, DME supplemented to contain 10% FCS, 20 mM HEPES, groups of mice were injected s.c. in the footpad with 1 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM 1 10 6 PFU of d301 or KOS1.1 virus. At 5 min after inoculaglutamine. Aliquots of 25 ml of each dilution were mixed tion, footpad tissue was collected from a pair of animals with an equal volume of partially purified virus in medium to assess the amount of recoverable virus. Then at 4 hr alone or containing complement (1:4 dilution of rabbit and 1, 2, and 3 days after inoculation, pairs of mice were low-tox H, Cedarlane, Hornby, Ontario, Canada) for final sacrificed and footpad tissue was collected into vials concentrations of 2 1 10 3 PFU/ml of virus and 1:8 dilution containing 1 ml assay medium and stored at 080Њ. Viral of complement. Mixtures containing complement were titers in the tissues were determined by plaque assay incubated at 37Њ for 80 min and mixtures lacking compleon S2 cells after samples were thawed and disrupted by ment were incubated at 4Њ for 80 min. Each was then sonication for 30 sec each.
mixed with an equal vol of a suspension of trypsinized For assessment of reactivating virus indicative of latent Vero cells at 4 1 10 5 /ml, and 100 ml were added to infection, trigeminal ganglia were removed from animals individual wells of 96-well flat-bottom tissue culture 28 days after corneal challenge and the tissue was enzyplates, six replicates per sample, for final concentrations matically dissociated by incubation in trypsin and collaof 100 PFU/well and 2 1 10 4 cells/well. After 3 days of genase as previously described (Kennedy et al., 1980;  incubation at 37Њ and 5% CO 2 , wells were scored for the Leib et al., 1991) , except that after 30-min incubation at presence of CPE. Titers represent the reciprocal of the 37Њ, the tissue was pelleted and half of the dissociation final serum dilution preventing CPE in 50% of wells as medium was removed and replaced with serum-free meapproximated by the method of Reed and Muench (1938). dium, followed by another 30-min incubation. Dissociated Complement mixed with virus in the absence of HSVganglionic cells were added to Vero cell monolayers in specific serum antibody or in the presence of normal 6-well tissue culture dishes (1 ganglion/well). Wells were mouse serum had no effect on infectivity. observed for the presence of cytopathic effect (CPE) after 11 days of incubation at 37Њ and 5% CO 2 . Wells with no apparent CPE were collected, sonicated, and cultured on Assays of T cell proliferation fresh Vero cell monolayers to look for plaque formation.
For assessment of latency-associated transcript (LAT) HSV-specific T cell proliferative responses of splenocytes from two pooled spleens for each immunization expression in the trigeminal ganglia indicative of latent infection, trigeminal ganglia removed from mice immugroup were determined at various times after immunization, as described previously (Morrison and Knipe, 1994 ), nized twice with d301 or control cell lysate and then challenged 1 month later were frozen and serially secexcept that partially purified virus and control supernatant of uninfected cells were used as the in vitro stimuli. tioned at 8 mm using a cryostat microtome. Every other 
RESULTS
on the immune response of the host to the d301 mutant virus.
Mechanism of protection against latent infection by challenge virus
Duration of the protective immunity induced by a We had shown previously that immunization of mice replication-defective virus with replication-defective mutant viruses reduces the incidence of latent infection of the trigeminal ganglia by the Because replication-defective viruses possess properties of both inactivated or subunit vaccines and live virus wt challenge virus as assayed by reactivation following explant cocultivation (Morrison and Knipe, 1994) . This vaccines, it was unclear how durable the immune responses to a replication-defective mutant virus would be. reduction could be due to decreased establishment of latent infection or to decreased frequency of reactivation.
Of particular interest to infection with HSV is protection against latent infection because reduction in latency is To distinguish between these two possibilities, we measured the numbers of trigeminal ganglion neurons excrucial to lessening the severity of recurrent disease and the possibility for transmission. We could not measure pressing the LAT, a marker of latent infection (Stevens et al., 1987; Croen et al., 1987) , in animals immunized the duration of responses to inactivated virus because UV-inactivated virus had not protected against latent intwice with the replication-defective mutant virus d301 or inoculated with control cell lysate and challenged with fection by challenge virus or elicited detectable neutralizing antibody titers in our previous studies (Morrison and virulent virus by corneal inoculation. At 28 days postchallenge, the trigeminal ganglia were removed from the ani- . As a consequence, we compared the durability of the immune response induced by d301 and its mals and tissue sections from the ganglia were processed for in situ hybridization using a probe specific replication-competent parental wt virus, KOS1.1 in protecting against disease and acute and latent infection, for LAT (Leib et al., 1989) . The control animals showed approximately 20 LAT-positive neurons per section (Taas outlined in Fig. 1 . Groups of BALB/c mice (which are susceptible to HSV-mediated keratitis and latent infecble 1) while the d301-immunized animals showed a LATpositive neuron in only about one in four sections (Table  tion ( Harbour et al., 1981; Foster et al., 1986) ) were immunized s.c. in the rear flank with 2 1 10 6 PFU of d301, 1). These results allowed two conclusions about the mechanism of protection against latent infection. First, KOS1.1, or an equivalent amount of control cell lysate, and were immunized again 1 month later. Sera were immunization with d301 reduced the number of LAT-positive neurons (P õ 0.01) and therefore likely reduced the collected after each immunization to assess primary and secondary HSV-specific, neutralizing antibody responses. number of neurons that are latently infected by challenge virus. Thus, the protective effect was not simply a reducAt 1, 4, and 7 months after the second immunization, sera were again collected, and a cohort of mice was tion in the ability of the latently infected neurons to reactivate, the parameter measured previously (Morrison and sacrificed to assess the HSV-specific, T cell proliferative response. Subsets of the mice were then challenged by . Second, as evidenced by the lack of LATpositive neurons, d301 did not spread from the site of inoculation of virulent HSV-1 onto scarified corneas in an amount equivalent to 5 to 15 times the dose required immunization and establish latent infection in the trigeminal ganglion neurons, thereby saturating the reservoir of to produce encephalitis in 50% of the mice. The eyes of the mice were swabbed daily through 4 days postchalsites for latent infection in the trigeminal ganglion. Instead, the mechanism of protection seemed to be based lenge to determine viral titer in the tear film as a measure of acute replication. The mice were also monitored at but then remained constant through the following 7-month period ( Fig. 2A) . Complement-independent neuregular intervals for signs of encephalitis and keratitis. Surviving mice were sacrificed 28 days after challenge to tralizing antibody titers of these same sera were lower but were also similar for wt and mutant-infected mice assess the presence of latent infection in the trigeminal ganglia.
and remained roughly constant for 1-7 months after immunization (Fig. 2B) . Duration of immune responses. Sera collected from five or six mice of each immunization group were tested
To examine the durability of a T cell memory response, we examined T cell proliferative responses at various for HSV-specific neutralizing antibody in a CPE inhibition assay. Titration of complement-dependent neutralizing times after immunization. We detected a strong T cell proliferative response from splenocytes of either mutant antibodies ( Fig. 2A) showed a primary antibody response 21 days after the first immunization with mutant or wt or wt virus-immunized mice at 1, 4, and 7 months after immunization (Fig. 3) . The response was HSV-specific in virus. The titers were augmented greatly and to similar extents by secondary immunization with the mutant or that control supernatant placed in culture stimulated only low levels of incorporation compared to responses to wt virus. The titers in both mutant and wt virus-immunized mice declined by 60-75% during the ensuing 3 weeks HSV-infected lysate (Figs. 3A and 3B), except that back-
FIG. 2.
Neutralizing antibody titers in sera from immunized mice. Sera were collected from groups of six mice at the indicated times after immunization, and HSV-specific neutralizing antibody titers of pooled sera were determined in a CPE inhibition assay. Titers shown represent a statistical approximation of the reciprocal of the highest serum dilution giving 50% inhibition of CPE. CL, control cell lysate. (A) Complementdependent titers; (B) complement-independent titers. immunized with wt virus through at least 7 months after immunization, and that HSV-specific immunity existed in the mutant virus-immunized mice at each time of challenge.
Duration of protection against acute viral replication in the eye. We assessed whether the immune response elicited by immunization with replication-defective virus maintained over time the capacity to reduce viral replication at the initial site of infection in the eye. Less virus was shed in the tear film of mice immunized with mutant virus than in mice inoculated with control cell lysate when both groups of mice were challenged 1 month later (Fig. 4A) . This capacity of the immune response to reduce viral titer in the eye was maintained in mice challenged at 4 or 7 months after the final immunization (Figs. 4B  and 4C ). Differences in viral eye titer of 1 to 2 log between control and immunized mice were apparent as early as 1 day after infection. Mice immunized with mutant or wt virus showed similar reductions in eye titer at 1 and 4 months, and the reduction was strikingly equivalent at 7 months (Fig. 4) .
Duration of protection against encephalitis and keratitis. By 5 days postchallenge, mice inoculated twice with control cell lysate uniformly developed signs of encephalitis when challenged at 1, 4, or 7 months after immunization: 88, 100, and 86% of the mice eventually succumbed to infection at the three times, respectively. In contrast, mice immunized twice with replication-defective or wt virus showed no signs of encephalitis whether challenged at 1, 4, or 7 months after immunization. Severe keratitis with stromal lesions also was observed in mice inoculated with control cell lysate, with mean keratitis scores reaching 3/ after challenge at all three times (Fig. 5) . Immunization with mutant or wt virus completely protected mice challenged at 1 or 4 months from development of stromal disease (Figs. 5A and 5B) and protected most mice challenged at 7 months (Fig. 5C ). However, at 7 months, focal lesions of the cornea were seen in three of the eyes of both mutant and wt virus-immunized mice beginning 14 days after challenge. In 2/14 or 1/12 eyes from mutant or wt-immunized mice, respec- nisms could not be determined. Thus, there was less acute replication of challenge virus in the eyes of mutant virus-immunized mice and lower incidence of disease ground proliferation was much higher at 7 month (Fig.  3C) . Furthermore, the proliferative response of splenocompared with control mice at all times although there was some evidence of waning protection by 7 months cytes from mutant virus-immunized mice was maintained at a level nearly equivalent (1 month) or equivalent (4 in both wt and mutant virus-immunized mice.
Duration of protection against latent infection.
We asand 7 months) to that seen in mice immunized with wt virus. These results indicated that mice immunized with sessed whether the immune response to replication-defective virus maintained over time its capacity to dereplication-defective virus maintained neutralizing antibody and T cell proliferative responses as well as mice crease latent infection of the nervous system by chal-tent infection with the capacity for reactivation (Leib et al., 1991; Jacobson et al., 1993) . When challenged at 1 month after immunization, none of the ganglia from wt virus-immunized mice and only 17% of ganglia from mutant virus-immunized mice contained reactivating challenge virus. Cultures of all ganglia from surviving mice inoculated with control cell lysate showed evidence of regarded as the most sensitive means of assessing la- (Fig. 6) , and that its parent, the KOS1.1 strain, does one experiment (Fig. 6A ) and up to 6 days after inoculab Compared to control cell lysate-inoculated mice by Fisher's exact tion in a second experiment of longer duration (Fig. 6B ).
test.
Titration on Vero cells of Day 1 and Day 3 samples from c Not determined.
d301 mutant-infected mice showed no plaques (results not shown), confirming that the virus persisting in the footpads was truly input mutant virus. The persistence reactivating virus (Table 2 , Expt 1), consistent with previous observations (Morrison and Knipe, 1994) . Mice chalof the mutant virus in an infectious form may prolong the period of time during which infection and expression of lenged at 4 months after immunization also were apparently protected from latent infection of the trigeminal ganviral gene products occurs, thereby increasing the host immune response to the replication-defective virus even glion by challenge virus: 0 and 10% of ganglia from mutant and wt virus-immunized mice, respectively, conif the virus does not spread from the primary cells it infects. tained reactivating virus. These data from the 4-months time point could not be compared with time-matched controls, however, because all mice inoculated with con-DISCUSSION trol cell lysate died as a result of challenge virus infecThis work has addressed the mechanisms by which tion. A separate experiment in which more control mice a live virus induces protection against a persistent infecsurvived the challenge confirmed the apparent protection tion and, specifically, how a replication-defective mutant seen at 1 and 4 months (Table 2, Expt 2). At 7 months, of HSV induces protection against latent infection by all control ganglia but only 17% of ganglia from mice challenge HSV. We have shown that immunization with immunized with wt virus contained reactivating challenge the mutant virus reduces the number of trigeminal ganvirus. Although the mice immunized with wt virus showed glion neurons expressing the LAT transcript, arguing that a reduction in latent infection, the reduction was not stathe number of neurons latently infected by challenge vitistically significant. Reduction in the incidence of reactirus was reduced by a mechanism other than establishvation was observed also in mutant virus-immunized ment of latency in those neurons by the immunizing virus. mice in which 42% of trigeminal ganglia showed reactivaSecond, the duration of immunity induced by the mutant tion, but this difference was also not statistically signifivirus at the chosen dose appeared to be nearly equivacant. These reactivation data indicate that protection lent to the replication-competent parental virus, demonagainst latent infection was maintained for at least 4 strating that the immunity induced by a replication-defecmonths following immunization with either mutant or wt tive mutant virus is durable like live viruses even though, virus.
like killed virus vaccines, the mutant virus cannot spread. In vivo replication phenotype of mutant virus. The obThird, the mutant virus showed no evidence of replication servation that a replication-defective virus effectively in vivo but was present in an infectious form for several stimulated long-term immunity analogous to live, replicadays in the mouse footpad, raising the possibility that tion-competent virus by all parameters tested was someprimary infection continues over an extended period of what surprising. We investigated the possibility that the time. replication-defective virus was as effective as wt virus in stimulating long-term immunity because its genetic deMechanism of protection against latent infection fect was somehow complemented in vivo, rendering it replication-competent. Mice were inoculated with mutant Our experiments show that animals immunized with the replication-defective mutant virus and challenged or wt virus in the footpad (as a form of s.c. immunization), and footpad tissue was collected at various times to with virulent HSV-1 bear approximately 80-fold fewer LAT-positive neurons than animals immunized with uninanimals immunized with the mutant virus and then challenged express LAT at 28 days after challenge. Furtherfected cell extract and then challenged. We conclude that immunization with the mutant virus reduces the nummore, LAT-positive neurons were not observed in dorsal root ganglia following inoculation of d301 into the footpad ber of latently infected cells and not merely the ability of the latent virus to reactivate. It is conceivable that in (Morrison and Knipe, unpublished results) . Therefore, the protection induced by the mutant virus is not the consethe immunized animals the challenge virus can establish latency but not express LAT. In situ hybridization techquence of saturation of the latent infection sites by a less virulent virus but rather appears to involve host immune niques have not been able to detect HSV DNA during latent infection, but a few recent studies have detected mechanisms. Other studies have, in fact, demonstrated that specific subsets of T cells are required for protection HSV DNA during latent infection through the use of in situ PCR techniques (Ramakrishnan et al., 1994; Gressens et against latent infection by the challenge virus (L. A. Morrison and D. M. Knipe, manuscript in preparation). al., 1994; Gressens and Martin, 1994; Mehta et al., 1995) . These papers differ in their conclusions regarding the latently infected cells in that one reports that the number Duration of immunity induced by a replicationof HSV DNA-positive neurons is 50-to 100-fold higher defective mutant virus than the number of neurons expressing LAT (Ramakrishnan et al., 1994) while another concludes that the distriThe capacity to provide long-lasting, ideally life-long, protection is an important attribute of an effective vacbution of LAT-positive cells approximates the distribution of HSV DNA-positive cells (Mehta et al., 1995) . We are cine-induced immune response. Historically, live viral vaccines have induced a more long-lived immunity than currently attempting to establish a reliable in situ PCR method to address the question of whether immunization killed virus vaccines. A major concern about replicationdefective viruses has been that they might not induce a reduces the number of neurons containing HSV DNA. If the number of latently infected cells is truly reduced by durable immunity because they could not spread to critical sites during infection of the host, much like killed immunization, the question remains as to whether the viral genome is prevented from reaching the neuronal virus vaccines. Nevertheless, at the dose used in mice in this study, the duration of immunity induced by the cell body or whether it reaches the neuronal cell body but cannot establish a latent infection. mutant virus seemed comparable to the replication-competent parental virus. The mice in this study were immuIt has been proposed that live, attenuated viruses can protect against the establishment of persistent infection nized as young adults at 6 and 10 weeks of age, and immunity was demonstrated to last until the mice are by a more virulent virus by occupying the cellular sites of latency and interfering with subsequent infection (Rud nearly 11 months old. For virgin, female BALB/c mice this protection covers approximately 2/3 of their adult lifespan et al., 1994) . Although it seemed unlikely that a replication-defective mutant could populate trigeminal ganglion (Russell, 1966) . The durability of immunity induced in mice by the replication-defective HSV mutant appears neurons after inoculation in the rear flank, our experiments rule out a form of latency involving LAT expression to approximate that of vaccinia vectors expressing HSV glycoprotein D (Rooney et al., 1988; Wachsman et al., by the mutant virus in the trigeminal ganglion by demonstrating that very few trigeminal ganglion neurons in the 1992) and may exceed that induced by glycoprotein sub-units (Meignier et al., 1987) where immunity against intraof the mutant virus to elicit strong, durable immunity in the absence of spread within the host. Further dose studcerebral challenge waned with increasing time after immunization.
ies are needed to better compare the immune responses induced by these two types of virus, but our results are It is interesting to note that in mice challenged 7 months after immunization, disease prevention and efconsistent with studies demonstrating that other replication-defective mutant viruses, including canarypox vecfects on acute replication remained largely unchanged from earlier times, but reduction of latent infection was tors (Cox et al., 1993) and vaccinia virus vectors (Sutter et al., 1994) , elicit immunity similar to replication-competent less dramatic. These results suggest two things. First, protection against latent infection may be the most sensiviruses. The survival of mutant virus in an infectious form in vivo and continued primary infection may provide a tive indicator of the efficacy of long-term protection against HSV infection. Consequently, even by the most way to reconcile current observations on the vaccine capabilities of replication-impaired mutant viruses with sensitive criterion, immunization with d301 was effective long-term in reducing challenge virus infection. Second, dogma about viral vaccines which holds that live forms of viral vaccines effectively stimulate immunity as a conwhile immune functions operating to reduce primary replication in the eye are still intact, those necessary to sequence of virus replication and spread (White and Fenner, 1986; Mims et al., 1993) . prevent virus spread to the nervous system and/or establishment of latent infection may not be operating as effectively at late times after immunization. Conceivably, one ACKNOWLEDGMENTS component of the immune response may have a shorter the mice challenged after 7 months, suggesting that some regulatory check on the activity of CD4 / T (Newell REFERENCES et al., 1989 ) cells may be lost over time. The question of
